AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01269645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Trial educational materials
Description: Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
Study NCT01269645 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Trial educational materials
Description: Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
Study NCT00834353 — intervention group
Intervention type: DRUG
Intervention: ATT
Study NCT04194333 — intervention group
Intervention type: PROCEDURE
Intervention: Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm
Description: Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
Study NCT00882245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Topical vehicle cream
Study NCT00882245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ointment
Description: SRD441 Ointment
Study NCT00659828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin
Description: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Study NCT01165060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
Study NCT02686567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with TDT
Description: After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
Study NCT04410770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood tracker ratings
Description: The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
Study NCT01486485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparinized saline priming group
Study NCT01486485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nafamostat infusion after heparinized saline priming
Study NCT05550610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Attention Training (MBAT) and Yoga
Description: Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
Study NCT01759485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
Study NCT01759485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01642667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prourokinase
Description: a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
Study NCT01642667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02965456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP 121 Lotion
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.
Study NCT02965456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Study NCT04562519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
Study NCT04562519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
Study NCT03555773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
Study NCT00792831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: Histone-Deacetylase Inhibitor
Study NCT02096939 — intervention group
Intervention type: PROCEDURE
Intervention: Adrenal extirpation
Study NCT02096939 — intervention group
Intervention type: DRUG
Intervention: Antihypertensive medication
Study NCT02898116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
Study NCT02898116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
Study NCT01384279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin, topiramate
Description: metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
Study NCT01846520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive FCPCI home education sessions
Study NCT01846520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive FCPCI telephone support sessions and 24 hour telephone support
Study NCT01846520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01846520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT04424524 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Direct-to-pharmacy oral PrEP refill visits
Description: Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
Study NCT01232205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronutrient antioxidant
Description: Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
Study NCT01232205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: supplementation with milk
Study NCT00744471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 10 mg IV every 8 weeks
Study NCT00744471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 5mg IV every 8 weeks
Study NCT00744471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 2.5 mg IV every 8 weeks.
Study NCT00744471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match tanezumab IV every 8 weeks
Study NCT00644748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg
Study NCT04478331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based physical activity interventions
Description: The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
Study NCT00775385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
Study NCT00775385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Customized Treatment
Description: Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)
Study NCT01488968 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation Treatment
Description: 39 radiation treatments
Study NCT01488968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation treatment
Description: 25 radiation treatments
Study NCT06025929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization technique
Description: Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.
Study NCT06025929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's mobilization techniques
Description: Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.
Study NCT06025929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT)
Description: Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
Study NCT06025929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Therapy (IFT)
Description: Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9% in 2 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 1 mg
Description: Dexamethasone 1 mg in 2 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2 mg
Description: Dexamethasone 2 mg in 2 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 3 mg
Description: Dexamethasone 3 mg in 2 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: Dexamethasone 4 mg in 2 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls
Study NCT02818491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls
Study NCT01604759 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Polarized Reflectance Spectroscopy System
Description: Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
Study NCT02732080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deferred coronary stenting
Description: Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
Study NCT02732080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate stenting
Description: Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
Study NCT02942589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal portion size
Study NCT02057380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous or IV
Study NCT02057380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV, Oral
Study NCT04159896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Description: Given PO
Study NCT04159896 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02543593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS or Sham tDCS
Description: tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
Study NCT02543593 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS or Sham tDCS
Description: tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
Study NCT03795779 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1-CD33 cCAR T cells
Description: CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
Study NCT02890056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H2GO!
Study NCT04119245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel supraglottic airway device
Description: After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
Study NCT04081545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics
Description: see arm/group description
Study NCT04081545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Opioid Analgesics
Description: see arm/group description
Study NCT00654238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400mg PO BID daily
Study NCT00859417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery
Description: Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
Study NCT00859417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perigee® prosthesis
Description: Surgical method with Perigee® prosthesis
Study NCT03752736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I wear sunscreen everyday song-based video
Description: All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet.
Study NCT01340534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen 80% FIO2
Description: Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
Study NCT01340534 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Use of air (no oxygen during surgery)
Description: No use of oxygen during surgery or in the 2 hours after the procedure.
Study NCT04850742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryopreserved aorta
Description: After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.
Study NCT02480075 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational Study only
Study NCT02496988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
Study NCT02496988 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CIK
Description: The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
Study NCT01164787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril
Description: Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
Study NCT01164787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik
Description: Mavik® 4 mg Tablets of Abbott Laboratories, USA.
Study NCT01305824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: PRT-201 10 micrograms administered at the time of AVF creation.
Study NCT01305824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered at the time of AVF creation.
Study NCT01305824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: PRT-201 30 micrograms administered at the time of AVF creation.
Study NCT02686567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without TDT
Description: After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
Study NCT01307358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare Interproximal (IP) Cleaning Prototype
Description: Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
Study NCT00057811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV, IT, or orally
Study NCT00057811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03715569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular function
Description: Vhit, Caloric test
Study NCT03715569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OAE/WBT
Description: Oto acoustic emissions Wide Band Tympanometry
Study NCT00057811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or IT